CeriBell (NASDAQ:CBLL) Receives $32.60 Average PT from Brokerages

CeriBell (NASDAQ:CBLL) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $32.60.

CBLL has been the topic of several analyst reports. William Blair assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating on the stock. TD Cowen lifted their target price on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. JPMorgan Chase & Co. began coverage on CeriBell in a report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price target on the stock. Canaccord Genuity Group upped their price objective on CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, Canaccord Genuity Group initiated coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price on the stock.

CeriBell Stock Down 0.5 %

Shares of CBLL stock opened at $22.96 on Friday. CeriBell has a 1 year low of $18.69 and a 1 year high of $32.75. The company’s fifty day simple moving average is $25.77.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million. On average, sell-side analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.